

## C-LINK® - Site-Specific Antibody Drug Conjugation

**C-LINK®** is an advantageous ADC conjugation technology to link varying payloads to antibodies and other proteins in a site-specific, enzymatic fashion.

**C-LINK®** stably couples payloads in an efficient and rapid 1-step reaction via a short peptide linker to the antibodies' C-terminus at physiological conditions, with fully controllable drug-antibody ratio (DAR).

**C-LINK®** does not affect antigen specificity, binding properties, antibody stability or manufacturability; the short peptide linker is non-immunogenic.

**ProBioGen** offers proof-of-concept (POC) studies, up to cell line and clinical antibody development.

The **C-LINK®** conjugation technology can directly link antibodies with a broad spectrum of different payload molecules, e.g. for oncology indications. The advantages are an efficient, site-directed, C-terminal conjugation without affecting the antibodies' specificity, binding properties or stability. The **C-LINK®** enzyme recognizes a 3-amino acid consensus sequence fused to the proteins' C-terminus, cleaves this sequence and attaches the payload by forming a new covalent peptide bond by a nucleophilic addition (transamidation) reaction. The 1-step enzymatic reaction is very efficient and completed in about 1 hour under very mild conditions. The fully controllable drug antibody ratio (DAR) can be extended to varying payloads at different sites, to bispecific antibody dimers, (sc)Fab's or any other protein. The short **C-LINK®** peptide linkers are designed to be minimally immunogenic.

ProBioGen offers in house POC studies up to stable cell line development and full antibody GMP manufacturing.

### C-LINK®

- Site-directed, enzymatic ADC conjugation technology
- Fully controllable drug antibody ratio (DAR)
- Stable, covalent payload conjugation
- C-terminal linking: distant from antigen binding site, unaffected manufacturability
- Full structural integrity and stability of the antibody
- Efficient, rapid 1-step enzymatic conjugation under mild conditions forms a new covalent peptide bond
- Peptide linker is short and minimally immunogenic
- Broad use: for antibodies, incl. bispecifics, Fab's, or any other recombinant protein
- Multiple drugs attachable to one site by modified peptide linker
- Multi-modal: different payloads on different sites
- POC studies up to full antibody GMP Production
- Royalty-free business model

### IP Position

Strong IP portfolio for **C-LINK®**, with the base technology patented in all major markets.

